表柔比星联合白蛋白紫杉醇治疗对晚期三阴性乳腺癌患者血清BRCA1及FOXA1水平的影响

Effect of epirubicin combined with albumin-paclitaxel on serum BRCA1 and FOXA1 levels in patients with advanced triple-negative breast cancer

目的分析晚期三阴性乳腺癌患者治疗过程中接受表柔比星联合白蛋白紫杉醇治疗的应用价值。方法选取2019年8月-2022年8月收治的晚期三阴性乳腺癌患者60例为研究对象,根据随机数字表法分为对照组与研究组,分别接受表柔比星与联合滴注白蛋白紫杉醇治疗。对两组临床疗效、血清指标、安全性与生活质量进行评估。结果对比观察两组临床疗效发现,研究组客观缓解率显著高于对照组,组间对比存在统计学差异(P<0.05);对比观察两组血清指标BRCA1、FOXA1、PF4、Ki-67、MMP-9、VEGF数据变化,研究组治疗后血清指标变化幅度大于对照组(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05);比较两组患者治疗后随访8个月生活质量评分发现,研究组高于对照组(P<0.05)。结论将表柔比星联合白蛋白紫杉醇应用于晚期三阴性乳腺癌患者治疗中,有助于改善血清指标,抑制血管内皮生长因子,应用安全性佳,利于改善患者预后,临床可进一步推广运用。

Objective To analyze the therapeutic value of epirubicin combined with albumin-paclitaxel in patients with advanced triplenegative breast cancer.Methods A total of 60 patients with advanced triple-negative breast cancer treated from August 2019 to August 2022 were selected as study subjects and divided into control group and study group according to random number table method.They received epirubicin and combined infusion of albumin-paclitaxel,respectively.Evaluation of clinical efficacy,serum markers,safety and quality of life.Results Comparing the clinical efficacy of the two groups,the objective remission rate of the study group was significantly higher than that of the control group,and there was a statistical difference between the two groups(P<0.05).The changes of serum indexes BRCA1,FOXA1,PF4,Ki-67,MMP-9 and VEGF were compared between the two groups.The changes of serum indexes in the study group after treatment were greater than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The quality of life(QOL)scores of the two groups were followed up for 8 months after treatment,and the QOL scores of the study group were higher than those of the control group(P<0.05).Conclusion The application of epirubicin combined with albuminpaclitaxel in the treatment of advanced breast cancer patients can help to regulate and improve serum indexes and inhibit vascular endothelial growth factor,with good application safety,which is conducive to improving the prognosis of patients,and can be further promoted in clinic.